ZNTL
ゼンタリス・ファーマシューティカルズ
ZNTL
ゼンタリス・ファーマシューティカルズ
Zentalis Pharmaceuticals, Inc. (ZNTL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Zentalis Pharmaceuticals, Inc. earns a cautious Buy rating, driven by azenosertib's potential in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). DENALI and ASPENOVA trials target accelera
Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a c